ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

13,743Medicare Part D Prescriptions Filled, Including Refills

Rank: 67 out of 1024

$723K Total Retail Price of All Prescriptions

Rank: 114 out of 1024

322 Patients Receiving at Least One Drug in Part D
92% Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Connecticut
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

10% of this provider’s 322 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

N/A

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $68 among peers.

Prescriptions per Patient

43 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
WARFARIN SODIUM 913 728 34 1 8
FUROSEMIDE 710 652 70 2 6
AMLODIPINE BESYLATE 450 421 65 3 3
METOPROLOL TARTRATE 443 426 74 4 7
LISINOPRIL 394 377 57 5 4
CYMBALTA 372 328 27 6 35
MIRTAZAPINE 362 351 64 7 31
TRAZODONE HCL 359 348 61 8 22
LEVOTHYROXINE SODIUM 313 294 42 9 2
ATORVASTATIN CALCIUM 285 273 47 10 1
ESCITALOPRAM OXALATE 252 247* 36 11 14
GABAPENTIN 249 202 28 12 18
SERTRALINE HCL 228 223* 25 13 23
NAMENDA 225 225 17 14 27
POTASSIUM CHLORIDE 220 220 22 15 30
LANTUS 211 160 27 16 53
METOPROLOL SUCCINATE 209 204* 36 17 12
QUETIAPINE FUMARATE 192 187* 28 A 18 44
OMEPRAZOLE 190 175 49 19 9
DONEPEZIL HCL 178 178 28 20 25
SIMVASTATIN 176 126 26 21 5
TAMSULOSIN HCL 174 169* 23 22 24
RISPERIDONE 166 166 21 A 23 48
METFORMIN HCL 130 116 22 24 10
CLOPIDOGREL 128 123* 20 25 28
DIVALPROEX SODIUM 119 114* 19 26 59
ATENOLOL 118 94 15 27 13
CARVEDILOL 115 110* 19 28 40
PREDNISONE 106 101* 24 29 38
IPRATROPIUM-ALBUTEROL 106 101* 36 29 80
LEVETIRACETAM 106 85 14 29 75
OLANZAPINE 105 82 14 A 32 73
CITALOPRAM HBR 101 96* 13 33 37
DIOVAN 98 <11 <11 34 21
LORAZEPAM 97 97 32 B 35 26
NOVOLOG 91 59 14 36 101
NIASPAN 91 <11 <11 36 244
HYDROCHLOROTHIAZIDE 90 85* 13 38 11
JANUVIA 84 84 12 39 45
LEVOFLOXACIN 84 79* 39 39 94
ENULOSE 82 82 14 41 124
BACLOFEN 81 <11 <11 42 98
ABILIFY 78 <11 <11 A 43 77
LIDODERM 75 70* 25 44 69
ISOSORBIDE MONONITRATE ER 72 <11 <11 45 63
KLOR-CON M20 71 71 14 46 70
RAMIPRIL 67 <11 <11 47 86
TRAMADOL HCL 66 66 30 48 36
DIGOX 66 66 13 48 81
HYDRALAZINE HCL 64 59* 12 50 91
CARBIDOPA-LEVODOPA 63 58* 11 51 92
SPIRONOLACTONE 61 <11 <11 52 71
CLONAZEPAM 53 40 11 B 53 57
VENLAFAXINE HCL ER 52 <11 <11 54 103
DILTIAZEM 24HR CD 50 <11 <11 55 110
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.